

# Cytoplasmic chromatin triggers inflammation in senescence and cancer

Zhixun Dou<sup>1</sup>, Kanad Ghosh<sup>1</sup>, Maria Grazia Vizioli<sup>2,3</sup>, Jiajun Zhu<sup>1</sup>, Payel Sen<sup>1</sup>, Kirk J. Wangenstein<sup>4</sup>, Johayra Simithy<sup>1,5</sup>, Yemin Lan<sup>1</sup>, Yanping Lin<sup>1,5</sup>, Zhuo Zhou<sup>6</sup>, Brian C. Capell<sup>1,7</sup>, Caiyue Xu<sup>1</sup>, Mingang Xu<sup>7</sup>, Julia E. Kieckhafer<sup>8,9</sup>, Tianying Jiang<sup>10</sup>, Michal Shoshkes-Carmel<sup>8,9</sup>, K. M. Ahasan Al Tanim<sup>1</sup>, Glen N. Barber<sup>11</sup>, John T. Seykora<sup>7</sup>, Sarah E. Millar<sup>7</sup>, Klaus H. Kaestner<sup>8,9</sup>, Benjamin A. Garcia<sup>1,5,12</sup>, Peter D. Adams<sup>2,3,13</sup> & Shelley L. Berger<sup>1,8,12,14</sup>

**Chromatin is traditionally viewed as a nuclear entity that regulates gene expression and silencing<sup>1–3</sup>. However, we recently discovered the presence of cytoplasmic chromatin fragments that pinch off from intact nuclei of primary cells during senescence<sup>4,5</sup>, a form of terminal cell-cycle arrest associated with pro-inflammatory responses<sup>6</sup>. The functional significance of chromatin in the cytoplasm is unclear. Here we show that cytoplasmic chromatin activates the innate immunity cytosolic DNA-sensing cGAS–STING (cyclic GMP–AMP synthase linked to stimulator of interferon genes) pathway, leading both to short-term inflammation to restrain activated oncogenes and to chronic inflammation that associates with tissue destruction and cancer. The cytoplasmic chromatin–cGAS–STING pathway promotes the senescence-associated secretory phenotype in primary human cells and in mice. Mice deficient in STING show impaired immuno-surveillance of oncogenic RAS and reduced tissue inflammation upon ionizing radiation. Furthermore, this pathway is activated in cancer cells, and correlates with pro-inflammatory gene expression in human cancers. Overall, our findings indicate that genomic DNA serves as a reservoir to initiate a pro-inflammatory pathway in the cytoplasm in senescence and cancer. Targeting the cytoplasmic chromatin-mediated pathway may hold promise in treating inflammation-related disorders.**

Chromatin undergoes global reorganization and degeneration during cellular senescence<sup>1,5,7–10</sup>, a stress response that associates with human diseases including cancer and ageing<sup>6</sup>. A hallmark of senescence is loss of the nuclear lamina protein lamin B1 (refs 7, 11, 12), leading to compromised integrity of the nuclear envelope<sup>4,5</sup>. Concomitantly, nuclear membrane blebs that contain chromatin fragments appear in senescent cells, which eventually partition into the cytoplasm to become cytoplasmic chromatin fragments (CCF)<sup>4,5</sup>. CCF contain genomic DNA,  $\gamma$ H2AX, and heterochromatin markers H3K9me3 and H3K27me3, but lack certain euchromatin markers, such as H3K9ac, indicating that CCF are derived from transcriptionally repressed heterochromatin regions and involve the DNA damage response<sup>4,5</sup>. The transport of genomic DNA to the cytoplasm is unusual, as nuclear DNA is regarded as a stable entity that encodes organismal genetic information. Whether cytoplasmic chromatin is associated with any biological function is unclear.


Senescence of multiple primary cell types, induced by oncogenic HRasV12, DNA damage, or replication exhaustion, exhibited CCF that stained with 4',6-diamidino-2-phenylindole (DAPI),  $\gamma$ H2AX,

and H3K27me3 (Fig. 1a and Extended Data Fig. 1a–c). Cytoplasmic DNA, typically a consequence of pathogen infection, can be recognized by the cytosolic DNA sensor cGAS, which produces a second messenger cyclic GMP–AMP (cGAMP) that activates STING<sup>13,14</sup>. The cGAS–STING pathway plays essential roles in restraining microbial infection and in triggering inflammation<sup>15–17</sup>. cGAS in proliferating cells displayed a diffuse pattern, but coalesced into sharp and bright puncta that co-localize with CCF in senescent cells (Fig. 1a and Extended Data Fig. 1c–f). cGAS activation, measured by the production of cGAMP, was detected in cells transfected with 90-mer double-strand DNA (dsDNA90), and, importantly, in senescent cells triggered by various means (Fig. 1b and Extended Data Fig. 1g). Moreover, STING showed hallmarks of activation in senescent cells, including formation of homo-dimers (Fig. 1c and Extended Data Fig. 1h) and redistribution into aggregates (Extended Data Fig. 1i, j). STING activation correlated with induction of CCF and expression of the pro-inflammatory gene *IL1 $\alpha$*  (Fig. 1c and Extended Data Fig. 1k). An alternative source of cytoplasmic chromatin in proliferating cells could be chromosome segregation errors, including micronuclei<sup>18,19</sup>. Together, these results indicate that cytoplasmic chromatin in senescence signals to the cGAS–STING pathway.

Activation of cGAS–STING leads to two downstream pathways: type I interferon through IRF3, and pro-inflammatory responses through NF $\kappa$ B<sup>16</sup>. Senescence associated with robust induction of CCF and pro-inflammatory genes, but not interferon genes (Extended Data Fig. 2a–e). The failure to induce interferon could be caused by activated p38 MAP-kinase (MAPK) in senescence<sup>20</sup>, as p38 inhibits STING-mediated interferon induction<sup>21</sup>. The p38 inhibitor SB203580 potentiated interferon- $\beta$  expression in senescence (Extended Data Fig. 2f). Furthermore, the cultured media derived from senescence, particularly *IL1 $\alpha$* , suppressed dsDNA90-induced interferon- $\beta$  (Extended Data Fig. 2g–i). The suppression of interferon in senescence is consistent with the observation that chronic interferon response can lead to activation of immune checkpoints<sup>22</sup>.

The secretion of pro-inflammatory cytokines is a key feature of senescence, referred to as the senescence-associated secretory phenotype (SASP)<sup>6</sup>. SASP is able to recruit immune cells, modulate their activity, and alter the tissue microenvironment<sup>6</sup>. The mechanisms that activate SASP involve a series of poorly understood events that are connected to the DNA damage response and NF $\kappa$ B<sup>23,24</sup>. We hypothesized that the CCF–cGAS–STING pathway promotes the SASP program.

<sup>1</sup>Department of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. <sup>2</sup>Beatson Institute for Cancer Research, Bearsden, Glasgow G61 1BD, UK. <sup>3</sup>Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G61 1BD, UK. <sup>4</sup>Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. <sup>5</sup>Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. <sup>6</sup>Biodynamic Optical Imaging Center (BIOPIIC), Beijing Advanced Innovation Center for Genomics (ICG), School of Life Sciences, Peking University, Beijing 100871, China. <sup>7</sup>Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. <sup>8</sup>Department of Genetics, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. <sup>9</sup>Center for Molecular Studies in Digestive and Liver Diseases, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. <sup>10</sup>Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. <sup>11</sup>Department of Cell Biology and the Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida 33136, USA. <sup>12</sup>Penn Epigenetics Institute, Department of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. <sup>13</sup>Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, California 92037, USA. <sup>14</sup>Department of Biology, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.




**Figure 1 | CCF activates cGAS–STING pathway in cellular senescence.**

**a**, Primary IMR90 cells stably expressing Flag-tagged cGAS were treated as indicated, and imaged under a confocal microscope. CCF are indicated by arrows. Scale bar, 10  $\mu$ m. **b**, Detection of cGAMP by nano-liquid chromatography–mass spectrometry (LC–MS). Left: cell metabolites were fractionated by HPLC, and the presence of cGAMP at  $m/z = 675.11$  ( $z = 1^+$ ) was measured. Right: tandem mass (MS2) spectra of the detected cGAMP. **c**, IMR90 cell lysates were subjected to immunoblotting. STING blots were performed under non-reducing conditions. \*STING dimer. SE, short exposure; LE, long exposure.

First, we stably reduced cGAS or STING expression (Fig. 2a and Extended Data Fig. 3a), and then induced senescence (Fig. 2b). While disruption of cGAS or STING did not affect several markers of senescence (Fig. 2c and Extended Data Fig. 3b), the activation of key SASP factors was greatly compromised (Fig. 2c and Extended Data Fig. 3c, d). We subsequently performed RNA sequencing (RNA-seq) in control and cGAS-deficient cells undergoing DNA-damage-induced senescence, using two independent biological replicates. Gene Ontology (GO) analysis of the top downregulated genes in cGAS-deficient cells revealed significant enrichment of the SASP program (Fig. 2d and Supplementary Table 1, and examples shown in Fig. 2e and Extended Data Fig. 3e). The global reduction of SASP is also presented by a heat map (Extended Data Fig. 3f). The role of cGAS–STING in mediating the SASP was confirmed at the secreted protein level in the conditioned media (Fig. 2f and Extended Data Fig. 3g, h).

We then asked whether cGAS–STING regulates SASP in established senescence. After establishment of senescence, STING or cGAS was inactivated, which did not revert senescence, but significantly reduced the expression of SASP genes (Extended Data Fig. 3i). By contrast, disruption of IFI16, a disputed cytosolic DNA sensor<sup>25</sup>, did not suppress SASP (Extended Data Fig. 3j, k). Taken together, these results indicate that cGAS–STING is required for both induction and maintenance of the SASP program.

We examined the DNA damage response and NF $\kappa$ B pathways that are involved in SASP<sup>23,24</sup>. Suppression of STING or cGAS had little




**Figure 2 | CCF–cGAS–STING pathway promotes the SASP.**

**a**, IMR90 cells as indicated were analysed by immunoblotting. **b**, Schematic illustration of experimental design. **c**, IMR90 cells were analysed by immunoblotting for senescence and SASP markers. **d**, GO analysis from RNA-seq, showing the most significant GO terms and the number of genes. **e**, Track views of *IL1* gene loci. **f**, Cytokine-array analyses of secreted factors in etoposide-induced senescent IMR90 cells. **g**, IMR90 cell lysates were analysed by immunoblotting. Quantification of p-p65 normalized to total p65 is shown. \* $P < 0.01$ , compared with Eto non-targeting control (NTC) condition,  $n = 3$  independent experiments, one-way analysis of variance (ANOVA) coupled with Tukey's post hoc test.

effect on p-ATM S1981, p-p53 S15,  $\gamma$ H2AX, senescence-associated heterochromatin foci (SAHF), or CCF in senescent cells (Fig. 2g and Extended Data Fig. 4a, b), but greatly compromised the activation of NF $\kappa$ B, as judged by phosphorylation of NF $\kappa$ B p65/RelA subunit on serine 536 (Fig. 2g), and nuclear translocation of the p65 subunit and its association with promoter regions of pro-inflammatory genes (Extended Data Fig. 4c, d). These data connect the cGAS–STING pathway with the NF $\kappa$ B-mediated SASP program.

We manipulated CCF and investigated the consequences. The generation of CCF is a consequence of compromised nuclear lamina integrity, mediated by loss of lamin B1 (refs 4, 5). Downregulation of lamin B1 leads to elevated CCF while overexpression of lamin B1 impairs the generation of CCF<sup>4,5</sup>. Overexpression of lamin B1 had little effect on the induction of  $\gamma$ H2AX, p-ATM S1981, and p-p53 S15, but significantly impaired the induction of CCF, STING dimer, p65 phosphorylation, and the SASP gene expression (Extended Data Fig. 4e–h). In contrast to reducing CCF, exogenous delivery of cytoplasmic DNA or chromatin fragments induced cGAS-dependent activation



**Figure 3 | STING mediates SASP in mice.** **a**, One week after ionizing irradiation, liver was analysed by immunohistochemistry and quantified.  $n = 8$  mice. Scale bar, 20  $\mu$ m. **b**, Representative images of mice 3 months after ionizing irradiation. **c**, **d**, Schematic illustration of constructs and experimental design. **e**, Immunohistochemistry analyses of liver. Clusters of immune cells are highlighted. Scale bar, 100  $\mu$ m.  $n = 8$  mice,  $*P < 0.005$ ,

$**P < 0.0001$ . **f**, Liver was harvested on day 6 and analysed by quantitative PCR with reverse transcription (RT-qPCR).  $n = 10$  mice for WT;  $n = 13$  mice for null. **g**, Luminescent imaging of mice.  $n = 3$  mice,  $*P < 0.05$ ,  $**P < 0.01$ . **h**, Representative images of liver tumours. Graphs show mean values with s.e.m.; unpaired two-tailed Student's  $t$ -test.


of SASP genes (Extended Data Fig. 4i–k). Taken together, these data demonstrate that the CCF–cGAS–STING pathway promotes the SASP program in primary human cells.

We subsequently used wild-type (WT) and *Sting*-null mice<sup>15</sup>, and exposed these mice to sub-lethal doses of ionizing irradiation that induced DNA damage, senescence, and the SASP program<sup>12,23</sup>. This procedure stimulated cGAMP and cytoplasmic chromatin in hepatocytes (Extended Data Fig. 5a, b). While ionizing irradiation promoted  $\gamma$ H2AX accumulation in the liver of both WT and null mice, the induction of IL1 $\alpha$  was significantly attenuated in the null mice (Fig. 3a and Extended Data Fig. 5c). Three months after ionizing irradiation, WT mice, but not the null mice, exhibited massive hair greying (Fig. 3b). Hence, STING mediates DNA damage-induced SASP and tissue inflammation *in vivo*.

We also investigated Ras-induced senescence *in vivo*. A vector with a Sleeping Beauty transposon that co-expressed NRasV12 and luciferase, together with a transposase construct, was delivered through hydrodynamic injection (Fig. 3c, d), leading to specific and stable expression of NRasV12 in hepatocytes. This procedure induces hepatocyte senescence, SASP, and inflammation, leading to immune-mediated clearance of pre-malignant hepatocytes<sup>10,26,27</sup>. NRasV12, but not the NRasV12/D38A mutant, induced inflammation (Fig. 3e top left and Extended Data Fig. 6a), and formation of cytoplasmic chromatin in hepatocytes

(Extended Data Fig. 6b). While senescence was comparable between WT and the null liver (Extended Data Fig. 6c–e), the null liver showed attenuated inflammation (Fig. 3e top right). Furthermore, the null liver possessed deficient induction of SASP genes and accumulation of immune cell markers (Fig. 3f and Extended Data Fig. 6f). The clearance of NRas hepatocytes was subsequently examined. While WT mice showed significantly reduced numbers of NRasV12-expressing cells from day 6 to day 12, the null mice failed to do so (Fig. 3e). Using the luciferase reporter co-expressed with NRasV12 (Fig. 3c), we found that WT mice showed gradual reduction of luciferase luminescence in the liver, whereas the luciferase activity persisted in the null mice (Fig. 3g). Impaired clearance of NRasV12-hepatocytes can lead to malignancies<sup>26</sup>. Eight months after the injection, intrahepatic tumours positive for NRas were observed in the null mice but not in the WT mice (Fig. 3h and Extended Data Fig. 6g). The role of STING in this model was confirmed by re-expression of STING in the null liver, which resulted in restoration of cytokine expression, inflammation, and immune-mediated clearance (Extended Data Fig. 7a–e). Taken together, these results demonstrate that STING *in vivo* is essential for Ras-induced SASP and immuno-surveillance.

While senescence and short-term inflammation is a potent barrier to tumorigenesis, persistent inflammation is associated with tissue damage, and in established cancers is linked to tumour growth



**Figure 4 | Cytoplasmic chromatin mediates pro-inflammatory responses in senescence evasion and cancer.** **a**, Scheme of experimental design. **b**, Senescence-associated  $\beta$ -galactosidase (SA- $\beta$ -gal) images of the three cell types. **c**, Confocal microscopy analyses of OIS-evaded cells. Scale bar, 10  $\mu$ m. **d**, Quantification of cells for parameters as indicated. Results are the average values of four different fields with over 200 cells. Error bars, s.d.; \* $P < 0.0001$ ; NS, non-significant; unpaired two-tailed Student's *t*-test. **e**, **f**, Cells as indicated were analysed by immunoblotting. **g**, CCLLE analyses of STING and lamin B1 with inflammatory gene expression profiles.

and metastasis<sup>6</sup>. Since cancers frequently contain extra-nuclear chromatin<sup>18,19</sup> and depend on NF $\kappa$ B for inflammation<sup>24</sup>, we investigated the role of cytoplasmic chromatin in pro-inflammatory responses in cells that evade senescence (either bypassing initiation of senescence or by escape after induction of senescence) and in human cancers in general.

To study senescence evasion, we first induced senescence of IMR90 cells by HRasV12, which were then either left untreated (termed as OISed) or were immortalized by stable expression of SV40 large T antigen and hTERT (termed as OIS-evaded) (Fig. 4a, b). Although the OIS-evaded cells showed loss of SAHF, they retained an elevated DNA damage response, cytoplasmic chromatin that strongly co-localized with cGAS (Fig. 4c, d, and Extended Data Fig. 8a), and the expression of pro-inflammatory genes, mediated by the cGAS–STING pathway (Fig. 4e, f, and Extended Data Fig. 8b, c). These observations suggest that, in transformed cells, the cytoplasmic chromatin-mediated pathway remains activated, and hence prompted us to investigate cytoplasmic chromatin in human cancers.

Although cancer cells may arise from various mechanisms, we found that cytoplasmic chromatin was present in multiple cancer cell lines (Extended Data Fig. 8d, e), consistent with studies showing nucleus-to-cytoplasm transport of nuclear DNA in cancer cells<sup>18,19</sup>. We discovered that cytoplasmic chromatin in the investigated cancer cells stained positive for DAPI and  $\gamma$ H2AX, co-localized with cGAS, and was negatively regulated by lamin B1 (Extended Data Fig. 8d–f). Moreover, the expression of pro-inflammatory genes was regulated by cGAS, STING, and lamin B1 (Extended Data Fig. 8g and Supplementary Table 2),

similar to that of senescent cells. Furthermore, analysis of ten breast cancer cell lines revealed that cytoplasmic chromatin associated with the expression of pro-inflammatory genes (Extended Data Fig. 8h and Supplementary Table 3).

To robustly examine the connection between the cytoplasmic chromatin-mediated pathway and pro-inflammatory gene expression in cancers at a larger scale, we exploited The Cancer Cell Line Encyclopedia (CCLE), which contains RNA-seq data sets for over 1,000 cell lines<sup>28</sup>. Cancer cells with the lowest and highest quarters of STING expression were grouped, and the expression of key pro-inflammatory genes was compared between the STING-low and STING-high subsets (Fig. 4g). This analysis revealed that higher STING expression was linked to significantly higher expression of pro-inflammatory genes, while interferon genes and the housekeeping gene GAPDH did not follow this pattern (Fig. 4g top and Extended Data Fig. 9a top). A similar trend was also observed with cGAS (Extended Data Fig. 9b). In contrast, lamin B1, but not lamin A/C, showed strong negative association with the pro-inflammatory genes (Fig. 4g bottom and Extended Data Fig. 9a, c), consistent with the observations that lamin B1, but not lamin A/C, regulates the cytoplasmic chromatin-mediated pathway<sup>4,5</sup>. The association of pro-inflammatory gene expression is specific to the cytosolic DNA-sensing pathway, because MAVS, a protein involved in cytosolic RNA sensing pathway, did not show this association (Extended Data Fig. 9d).

Furthermore, we exploited the RNA-seq database of human cancers from The Cancer Genome Atlas (TCGA), and again found that STING was significantly linked to the expression of pro-inflammatory genes in multiple cancers, including but not limited to pancreatic cancer, melanoma, prostate cancer, and breast cancer, while MAVS did not follow this pattern (Extended Data Fig. 10a–d and Supplementary Table 4).

Collectively, these data suggest that the cytoplasmic chromatin–cGAS–STING pathway is involved in expression of pro-inflammatory genes in cancer cells that evade senescence and in broad scenarios of human cancers in general.

In conclusion, this study establishes a functional role of cytoplasmic chromatin in mediating inflammation in senescence and cancer. This view suggests that genomic DNA not only carries central genetic information, but can also serve as a cytoplasmic ‘danger signal’ to alarm the immune system in coping with aberrant cellular activities. While clearly a short-term advantage in promoting immuno-surveillance of malignancies, this machinery may have a long-term destructive potential in creating genomic instability and in mediating tissue damage. While this paper was in revision, two related findings appeared that collectively support an essential role of the cytoplasmic chromatin–cGAS–STING pathway in mediating the SASP<sup>29,30</sup>. We envision that the cytoplasmic chromatin phenomenon may be involved in many biological processes beyond the current investigation.

**Online Content** Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.

Received 23 January; accepted 4 September 2017.

Published online 4 October 2017.

- Sen, P., Shah, P. P., Nativio, R. & Berger, S. L. Epigenetic mechanisms of longevity and aging. *Cell* **166**, 822–839 (2016).
- Benayoun, B. A., Pollina, E. A. & Brunet, A. Epigenetic regulation of ageing: linking environmental inputs to genomic stability. *Nat. Rev. Mol. Cell Biol.* **16**, 593–610 (2015).
- Berger, S. L. The complex language of chromatin regulation during transcription. *Nature* **447**, 407–412 (2007).
- Ivanov, A. *et al.* Lysosome-mediated processing of chromatin in senescence. *J. Cell Biol.* **202**, 129–143 (2013).
- Dou, Z. *et al.* Autophagy mediates degradation of nuclear lamina. *Nature* **527**, 105–109 (2015).
- Campisi, J. Aging, cellular senescence, and cancer. *Annu. Rev. Physiol.* **75**, 685–705 (2013).
- Shah, P. P. *et al.* Lamin B1 depletion in senescent cells triggers large-scale changes in gene expression and the chromatin landscape. *Genes Dev.* **27**, 1787–1799 (2013).

8. Capell, B. C. *et al.* MLL1 is essential for the senescence-associated secretory phenotype. *Genes Dev.* **30**, 321–336 (2016).
9. Sadaie, M. *et al.* Redistribution of the lamin B1 genomic binding profile affects rearrangement of heterochromatic domains and SAHF formation during senescence. *Genes Dev.* **27**, 1800–1808 (2013).
10. Tasdemir, N. *et al.* BRD4 connects enhancer remodeling to senescence immune surveillance. *Cancer Discov.* **6**, 612–629 (2016).
11. Shimi, T. *et al.* The role of nuclear lamin B1 in cell proliferation and senescence. *Genes Dev.* **25**, 2579–2593 (2011).
12. Freund, A., Laberge, R. M., Demaria, M. & Campisi, J. Lamin B1 loss is a senescence-associated biomarker. *Mol. Biol. Cell* **23**, 2066–2075 (2012).
13. Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. *Science* **339**, 786–791 (2013).
14. Wu, J. *et al.* Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. *Science* **339**, 826–830 (2013).
15. Ishikawa, H., Ma, Z. & Barber, G. N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. *Nature* **461**, 788–792 (2009).
16. Barber, G. N. STING: infection, inflammation and cancer. *Nat. Rev. Immunol.* **15**, 760–770 (2015).
17. Ishikawa, H. & Barber, G. N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. *Nature* **455**, 674–678 (2008).
18. Hatch, E. M., Fischer, A. H., Deerinck, T. J. & Hetzer, M. W. Catastrophic nuclear envelope collapse in cancer cell micronuclei. *Cell* **154**, 47–60 (2013).
19. Zhang, C. Z. *et al.* Chromothripsis from DNA damage in micronuclei. *Nature* **522**, 179–184 (2015).
20. Freund, A., Patil, C. K. & Campisi, J. p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. *EMBO J.* **30**, 1536–1548 (2011).
21. Chen, Y. *et al.* p38 inhibition provides anti-DNA virus immunity by regulation of USP21 phosphorylation and STING activation. *J. Exp. Med.* **214**, 991–1010 (2017).
22. Benci, J. L. *et al.* Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. *Cell* **167**, 1540–1554 (2016).
23. Rodier, F. *et al.* Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. *Nat. Cell Biol.* **11**, 973–979 (2009).
24. Chien, Y. *et al.* Control of the senescence-associated secretory phenotype by NF- $\kappa$ B promotes senescence and enhances chemosensitivity. *Genes Dev.* **25**, 2125–2136 (2011).
25. Gray, E. E. *et al.* The AIM2-like receptors are dispensable for the interferon response to intracellular DNA. *Immunity* **45**, 255–266 (2016).
26. Kang, T. W. *et al.* Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. *Nature* **479**, 547–551 (2011).
27. Acosta, J. C. *et al.* A complex secretory program orchestrated by the inflammasome controls paracrine senescence. *Nat. Cell Biol.* **15**, 978–990 (2013).
28. Barretina, J. *et al.* The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature* **483**, 603–607 (2012).
29. Gluck, S. *et al.* Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence. *Nat. Cell Biol.* **19**, 1061–1070 (2017).
30. Yang, H., Wang, H., Ren, J., Chen, Q. & Chen, Z. J. cGAS is essential for cellular senescence. *Proc. Natl Acad. Sci. USA* **114**, E4612–E4620 (2017).

**Supplementary Information** is available in the online version of the paper.

**Acknowledgements** We acknowledge S. Prouty for histology studies, E. Browning for small animal imaging, the Cell & Developmental Biology Microscopy Core, and the high-throughput screening core for technical assistance. We thank A. Brunet, J. Cross, J. Guerriero, I. Harel, E. J. Wherry, and W.-X. Zong for discussions and reading the manuscript. The Penn Skin Biology and Diseases Resource-based Center is supported by 1P30AR069589-01 (S.M.). Z.D. is supported by a fellow award from the Leukemia & Lymphoma Society and by National Institutes of Health (NIH) K99AG053406. S.L.B., P.D.A., and B.A.G. are supported by NIH P01AG031862. S.L.B. is supported by NIH CA078831, and B.A.G. by NIH P01CA196539. S.L.B. acknowledges support by the Glenn Foundation and the Ellison Foundation for research in ageing.

**Author Contributions** Z.D., Z.Z., P.D.A., and S.L.B. conceived the project. Z.D. and K.G. performed most of the experiments. M.G.V. contributed Fig. 3a, b and Extended Data Fig. 5b, c. J.Z. contributed Fig. 4g and Extended Data Figs 9 and 10. P.S., B.C., C.X., and Y.Lan contributed Fig. 2d, e and Extended Data Fig. 3e, f. K.W. and K.K. advised on Fig. 3c–h and Extended Data Fig. 6. J.S., Y.Lin, and B.G. contributed Fig. 1b, Extended Data Figs 1g and 5a. M.X., J.K., T.J., M.S.-C., J.T.S., and S.M. contributed histology analyses in Fig. 3 and Extended Data Fig. 6. K.M.T. contributed plasmids in Figs 1–3. G.B. contributed STING mice and advised on *in vivo* experiments. Z.D., P.D.A., and S.L.B. composed the manuscript. All authors reviewed the manuscript and discussed the work.

**Author Information** Reprints and permissions information is available at [www.nature.com/reprints](http://www.nature.com/reprints). The authors declare no competing financial interests. Readers are welcome to comment on the online version of the paper. Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Correspondence and requests for materials should be addressed to S.L.B. ([bergers@upenn.edu](mailto:bergers@upenn.edu)) or P.D.A. ([padams@sbbpdiscovery.org](mailto:padams@sbbpdiscovery.org)).

**Reviewer Information** Nature thanks J. van Deursen, K.-P. Hopfner and the other anonymous reviewer(s) for their contribution to the peer review of this work.

## METHODS

**Cell culture and treatment.** Primary IMR90 and BJ fibroblasts were described previously and were authenticated by genome-wide sequencing analyses<sup>5,7</sup>. The cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 100 units ml<sup>-1</sup> penicillin, and 100 µg ml<sup>-1</sup> streptomycin (Invitrogen), and were intermittently tested for mycoplasma. The cells were cultured under physiological oxygen (3%), and were used within population doubling of 35, except for replicative senescence experiments. For etoposide-induced senescence, IMR90 cells at approximately 60–70% confluency were treated with 100 µM etoposide for 48 h. The media were then replaced and cells were harvested at day 7. For BJ cells, 40 µM etoposide was added to the culture media throughout the treatment. IMR90 stably expressing ER:HRas was described previously<sup>5</sup>. Senescence-associated β-galactosidase was performed as previously described<sup>5,31</sup>. dsDNA90 was described elsewhere<sup>32</sup>, and transfected using Lipofectamine 2000; transfected cells were harvested 1 day after transfection for analysis of interferon-β and after 4 days for pro-inflammatory cytokines.

**Mice experiments.** STING<sup>+/+</sup> and STING<sup>-/-</sup> mice in C57BL/6 background were described elsewhere<sup>15</sup>. Mice were fed *ad libitum* on a regular diet, and all procedures were approved and performed following institutional regulations and guidelines (University of Pennsylvania and University of Glasgow). Both sexes were included in the study. Hydrodynamic tail vein injection was performed as previously described<sup>33</sup>. In brief, 20 µg of NRasV12/luciferase and 10 µg of transposase constructs were injected to mice that were 8–12 weeks old in Ringer solution that corresponded to 10% of the body weight (for example, 2.0 ml for a 20 g mouse, but not over 2.5 ml if the mouse was more than 25 g) within 6 s. Mouse *Sting* cDNA was purchased from Origene and was cloned into the NRas/IRES/luciferase vector. All constructs were verified by DNA sequencing. For *in vivo* luciferase imaging, luciferin was intraperitoneally injected to mice at 150 mg/kg (body weight). The mice were anaesthetized using isoflurane and imaged under an IVIS Spectrum imager every minute for 15 min. Images with peak signals were used for data analyses. Identical parameters were used for longitudinal study and for comparisons between the two cohorts of mice. For ionizing radiation, mice were subjected to a sub-lethal dose of 4 Gy irradiation, and were harvested 7 days after the procedure for immunohistochemistry studies. Presented images of mice after ionizing irradiation are representative of no fewer than five mice per condition. Isolation of primary hepatocytes is described elsewhere<sup>33</sup>. Liver tumour studies were performed following institutional regulations and guidelines (University of Pennsylvania, animal protocol number 805175). A maximal loss of 20% of body weight was considered as an endpoint. None of the experiments exceeded the limit. Immunohistochemistry was performed using standard procedure at the institutional histology core facilities and was scored in a double-blinded manner. **Reagents and antibodies.** Etoposide, 4-hydroxytamoxifen, puromycin, and polybrene were purchased from Sigma. Hygromycin was from Gemini Bio Products, and luciferin was from PerkinElmer. Recombinant human IL1α protein (used at 20 ng ml<sup>-1</sup>) was from R&D Systems, and p38 MAPK inhibitor from Selleck Chemicals.

The following antibodies were described previously: Flag, p16, lamin B1, GAPDH, and GFP<sup>5</sup>. Other antibodies used included γH2AX (Abcam ab2893 and Cell Signaling Technology 9718), STING (Cell Signaling Technology 13647 and LSBio LS-B7237), cGAS (Cell Signaling Technology 15102 and Santa Cruz Biotechnology sc-245858), human IL1α (Abcam ab9614), IL8 (Abcam ab18672), p-ATM S1981 (Abcam ab12922), p-p53 S15 (Cell Signaling Technology 9284), p-p65 S536 (Cell Signaling Technology 3033), p65 (Cell Signaling Technology 8242), NRas (Santa Cruz Biotechnology sc-31), CD3 (Abcam ab16669), Mac2 (BioLegend 125401), mouse IL1α (R&D Systems AF-400), p21 (sc-471), and H3 (Active Motif 39763).

**Retrovirus and lentivirus.** Retroviral GFP, GFP-lamin B1, WZL-HRasV12 constructs, and production of virus for stable expression were as previously described<sup>5</sup>. Retroviral constructs (including LPC-cGAS-Flag) were transfected to Phoenix packaging cell line. Lentiviral pLKO constructs were transfected with packaging plasmids to HEK293T cells. Viral supernatant was filtered through a 0.45 µm filter, supplemented with 8 µg ml<sup>-1</sup> polybrene, and mixed with trypsinized recipient cells. The infected cells were then selected with puromycin or hygromycin.

pLKO-based shRNA was from Sigma. The following shRNAs were used. STING (TRCN0000163296: GCCCGATTGCAACTTACAAT and TRCN0000161345: GTCCAGGACTTGACATCTTAA), cGAS (TRCN0000149984: CAACTACGACTA AAGCCATTT and TRCN0000128706: CGTGAAGATTTCTGCACCTAA), IFI16 (TRCN0000364688: GGAAACTCTGAAGATTGATAT and TRCN0000364735: CTGGATGTCATTGACGATAAT), and lamin B1 (TRCN0000029269: CCAGGG AAGAACTGATGGAAA and TRCN0000029271: GCATGAGAATTGAGA GCCTTT).

**Immunoblotting.** Western blotting was performed as previously described<sup>5</sup> with slight modifications. Cells were lysed in buffer containing 50 mM Tris

pH 7.5, 0.5 mM EDTA, 150 mM NaCl, 1% NP40, 1% SDS, supplemented with 1:100 Halt Protease and phosphatase inhibitor cocktail (Thermo Scientific). The lysates were briefly sonicated, and supernatants were subjected to electrophoresis using NuPAGE Bis-Tris precast gels (Life Technologies). For p-ATM S1981 blotting, cells were lysed in 20 mM Tris, pH 7.5, 137 mM NaCl, 1 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, 1% NP-40, 10% glycerol, supplemented with 1:100 Halt Protease and phosphatase inhibitor cocktail (Thermo Scientific) and benzonase (Novagen) at 12.5 U ml<sup>-1</sup>. The lysates were rotated at 4 °C for 1 h, and supernatants were loaded. For immunoblotting of STING dimer, reducing reagent was not added to the lysates before loading. After transferring to nitrocellulose membrane, 5% milk in TBS supplemented with 0.1% Tween 20 (TBST) was used to block the membrane at room temperature for 1 h. Primary antibodies were diluted in 5% BSA in TBST, and incubated at 4 °C overnight. The membrane was washed three times with TBST, each for 10 min, followed by incubation of horseradish-peroxidase-conjugated secondary antibodies at room temperature for 1 h, in 5% milk/TBST. The membrane was washed again three times, and imaged by films or by a GE Amersham Imager 600.

**Immunofluorescence and quantification.** Immunofluorescence was performed as previously described<sup>5</sup>. In brief, cells were fixed in 4% paraformaldehyde in PBS for 30 min at room temperature. Cells were washed twice with PBS, and permeabilized with 0.5% Triton X-100 in PBS for 10 min. After washing two times, cells were blocked in 10% BSA in PBS for 1 h at room temperature. Cells were then incubated with primary antibodies in 5% BSA in PBS supplemented with 0.1% Tween 20 (PBST) overnight at 4 °C. The next day, the cells were washed four times with PBST, each for 10 min, followed by incubation with Alexa Fluor-conjugated secondary antibody (Life Technologies), in 5% BSA/PBST for 1 h at room temperature. The cells were then washed four times in PBST, incubated with 1 µg ml<sup>-1</sup> DAPI in PBS for 5 min, and washed twice with PBS. The slides were mounted with ProLong Gold (Life Technologies) and imaged with a Leica TCS SP8 fluorescent confocal microscope. Quantification of the percentage of positive cells of SAHF, p-ATM, IL8, γH2AX, and p65 was done under identical microscopy settings between samples. Cells with more than five visible spots at the expected location were considered positive. Over 200 cells from 4 randomly selected fields were analysed.

**RT-qPCR.** mRNA from cells or tissues were extracted with an RNeasy Mini Kit (Qiagen), with a DNase I (Qiagen) digestion step to minimize genomic DNA contamination. Reverse transcription was done using a High-Capacity RNA-to-cDNA Kit (ThermoFisher), and then qPCR was performed using a 7900HT Fast-Real-Time PCR platform (ABI). Results were normalized to GAPDH for human cells.

The following primers were used for RT-qPCR of human cells. IL1α: TGTAAGCTATGGCCACTCCA, AGAGACACAGATTGATCCATGCA; IL1β: CTCTCTCCTTTCAGGGCCAA, GAGAGGCCTGGCTCAACAAA; IL6: CACCGGGAACGAAAGAGAAG, TCATAGCTGGGCTCCTGGAG; IL8: ACATGACTTCCAAGCTGGCC, CAGAAATCAGGAAGGCTGCC; MMP3: GGATGCCAGGAAAGGTTCTG, CCAGGTGTGGAGTTCCTGATGT; GAPDH: CAGCCTCAAGATCATCAGCA, TGTGGTCATGAGTCCCTTCCA; STING: ATATCTGCGGCTGATCCTCG, TTGTAAGTTCGAATCCGGGG; cGAS: GGCGGTTTTGGAGAAGTTGA, GCCCGCTGGAGATATCAT; IFI16: CTACCCAGGAACAGCTGGC, GGTTGTGCTGGCTGGAAG; p16: CCAACGCACCGAATAGTTACG, CCATCATCATGACCTGGATCG; lamin B1: CTCTCGTCGATGCTGACAG, TCCCTTATTCCGCCATCTCT.

For mouse liver NRas/luciferase-related RT-qPCR, three pieces of liver from the same mouse were combined as one sample ( $n = 1$ ), and the mRNA and reverse transcription were performed as previously described. The results of SASP factors were normalized to the value of luciferase as an internal control for NRas abundance.

The following primers were used for RT-qPCR of mouse tissues. IL1α: AGGAGAGCCGGGTGACAGTA, TCAGAATCTCCCGTTGCTTG; IL1β: CCAAAAGATGAAGGGCTGCT, TCATCAGACAGCCAGGTC; IL8: CTGGTCCATGCTCCTGCTG, GGACGGACGAAGATGCTAG; CXCL1: CAATGAGCTGCGTGTGCTAGT, TTGAGGTGAATCCAGCCAT; MMP3: TGGAGCTGATGCATAAGCCC, TGAAGCCACCAACTCAGGA; CD45: CGCGGTGTA AAACTCGTCAA, CCCC AAAATCTGTCTGCACATT; CD3: CAAGAGCTGCCTCAGAAGA, CGAGAAATCTGGAGCAGCA; B220: CGCGGTGTA AAACTCGTCAA, CCCC AAAATCTGTCTGCACATT; CD68: TGGCGGTGGAATACAATGTG, TGAATGTCCACTGTGCTGCC; Klrd1: TCTG AATGTGTGTTTGCTG, ACAATTGCACCTGATGCCCAA; Luciferase: CGCTGGAGAGCAACTGCATA, CCAGAAACCAGGGCGTATCT; GAPDH: GGAGCGAGACCCCACTAACA, ACATACTCAGCAGCCGCTC; 18s: GTAA CCGTGAACCCCAT, CCATCCAATCGGTAGTAGCG.

**Chromatin immunoprecipitation.** Chromatin immunoprecipitation was performed as previously described<sup>5</sup> with slight modification. Cells were crosslinked with 1% formaldehyde diluted in PBS for 5 min at room temperature. After glycine quenching, the cell pellets were lysed in buffer containing 50 mM Tris, pH 7.4,

150 mM NaCl, 1% Triton X-100, 0.1% SDS, supplemented with complete protease inhibitor cocktail (Thermo Scientific), and sonicated with a Covaris sonicator, resulting in chromatin fragments of 250 bp average size. The supernatant was diluted ten times with the above buffer without SDS, and subjected to immunoprecipitations with 1 µg of p65 antibody or control IgG conjugated with Dynabeads Protein A (Invitrogen) at 4 °C overnight. The beads were then washed four times with buffer containing 50 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, and one time with final wash buffer (50 mM Tris, pH 8.0, 10 mM EDTA, 50 mM NaCl), followed by elution with incubation of elution buffer (final wash buffer plus 1% SDS) at 65 °C for 30 min with agitation in a thermomixer. The chromatin immunoprecipitation and input were then purified and used for qPCR analysis.

The following primers were used for qPCR of gene promoter regions. IL8: CCACCGGAAGGAACCATCT, GGCCAGCTTGAAGTATGT; IL6: CACC TGGAGACGCCTTGAAG, TGCCTGGCCATCCTCAAAT; MMP3: TGGAT TTGCTGGTTCTTGAGG, TTTGTTCTATTCTGCCATGAGG;  $\beta$ -actin: CTGGGTTTATAGGGCGCC, AAGTTGCCTTTATGGCTCGAG.

**RNA-seq.** RNA-seq was performed as previously described<sup>7,8</sup> with modifications. Total RNA was isolated from IMR90 cells using an RNeasy kit (Qiagen) and 1 µg of RNA was used as input in a Scriptseq Complete kit (Epicentre). In brief, total RNA was ribo-depleted using a Ribozero magnetic protocol (Epicentre). The ribo-depleted RNA was then ethanol-precipitated, fragmented, and tagged at both ends for stranded library preparation, using the Scriptseq v2 library preparation protocol. The PCR amplification step was used to index the libraries, and multiplexed libraries were quantified by Bioanalyzer (Agilent) and qPCR (Kapa Biosystems). The RNA-seq run was performed on the NextSeq 500 platform (Illumina).

Single-ended, 75 bp reads were mildly trimmed using Trimmomatic (version 0.32) to remove leading or trailing nucleotides whose sequencing quality was below 3. Reads whose length fell below 30 bp after trimming were also removed from downstream analysis. STAR (version 2.3.0e) was used for mapping reads to reference genome (hg19), requiring a minimum alignment score of 10. The expression level of RefSeq genes was quantified using featureCounts (version 1.5.0) and normalized using DESeq2.

Gene expression of RNA-seq data was compared in log<sub>2</sub>-CPM (that is, log<sub>2</sub>(reads per million mapped reads)) as reported by DESeq2. The average log<sub>2</sub>-CPM values were used for biological replicates. Genes with over threefold change in expression between etoposide-treated sh-NTC and sh-cGAS were uploaded to DAVID for GO analysis. Genes contributing to the top four downregulated GO terms were combined with known SASP genes<sup>34</sup> for heat map visualization, where expression of each gene was scaled to between 0 and 1 on the basis of its minimum and maximum values in proliferating, etoposide-treated sh-NTC and sh-cGAS. SASP genes that were induced less than threefold (comparing etoposide-treated sh-NTC and proliferating) and those that were not induced in IMR90 DNA damage conditions<sup>34</sup> were not included for the heat map.

RNA-seq data were uploaded to the Gene Expression Omnibus under accession number GSE99028.

**Secreted cytokine analysis.** For western and cytokine-array analysis of secreted cytokines, cells were cultured in serum-free media for 24 h. The cultured media were then collected, and the cell numbers were counted for normalization. The media were filtered with a 0.45 µm PVDF filter (Millipore) to remove cells and debris. The resulting supernatant was further concentrated with a 3 kDa Amicon Ultra 0.5 mL centrifugal filter (Millipore), and was subjected to immunoblotting of IL8 or cytokine-array assay (RayBiotech, Human Cytokine Array C1) following the manufacturer's guidelines. The intensities of array dots were quantified with Fiji and normalized against the positive controls on the blots.

**Chromatin fragment extraction and transfection.** Extraction of chromatin fragments was performed as previously described<sup>35</sup> with modifications. In brief, proliferating IMR90 cells were incubated with hypotonic buffer (10 mM Tris, pH 7.4, 30 mM NaCl, 3 mM MgCl<sub>2</sub>, 0.1% NP40), supplemented with protease inhibitor cocktail, on ice for 10 min. The cells were then centrifuged at 300g, 4 °C, for 3 min. The supernatant was carefully removed, and the resulting pellets were incubated with benzonase buffer (50 mM Tris pH 7.5, 300 mM NaCl, 0.5% NP40, 2.5 mM MgCl<sub>2</sub>) and protease inhibitor cocktail, supplemented with 10 U benzonase, on ice, for 30 min. The product was centrifuged again at 300g, 4 °C, for 3 min, and benzonase was inactivated by addition of 15 mM EDTA. The resulting supernatant contained chromatin fragments and soluble nuclear proteins. The product was then diluted five times with PBS. As a control, buffer without benzonase was used, which yielded soluble nuclear proteins but no chromatin fragments. The chromatin fragments or the control were transfected to proliferating IMR90 cells using Lipofectamine 2000. Successful transfection was confirmed by immunofluorescence with an H3 antibody and DAPI. Transfected cells were harvested 4 days after transfection, and were analysed by RT-qPCR for cytokine production.

**2/3'-cGAMP detection by LC-MS/MS.** cGAMP extraction was performed as reported in ref. 36, with slight modifications. IMR90 cells were cultured in 10-cm dishes, and the culture media were removed and replaced with 2 ml 80:20 methanol:water. The dishes were incubated at -80 °C overnight, and cells were scraped, subjected to two vortex, freeze/thaw cycles in liquid nitrogen, and sonicated in a Bioruptor sonicator in ice water bath. The product was clarified by centrifugation at 21,000g for 20 min at 4 °C, and the supernatant was concentrated by a SpeedVac concentrator and subjected to sample clean-up and LC-MS analysis. For mouse hepatocytes and liver, tissues were homogenized in 80:18:2 methanol:water:acetic acid, and were processed similarly as previously described. The pellets from the centrifugation step were dissolved in 1% SDS followed by sonication, and the concentration of proteins was measured by a Pierce BCA Protein Assay Kit, allowing normalization to total proteins.

Dried supernatants were resuspended in 50 µl 0.1% acetic acid and subjected to solid-phase extraction. In brief, the bottom of a P200 pipette tip was sealed with a small disc of C18 material (Millipore). To the pipette tip, 200 µl of phenyl-hexyl resin (5 µm, 100 Å, Phenomenex) resuspended in acetonitrile was added. A centrifuge adaptor was used to hold stage-tips in place in 1.5 ml microcentrifuge tubes. The resin was flushed with 50 µl of acetonitrile by slow centrifugation. The resin was then equilibrated with 50 µl of 0.1% acetic acid and samples were loaded onto the equilibrated resin. Samples were washed once with 0.1% acetic acid and eluted into a clean microcentrifuge tube by flushing 50 µl of 20% acetonitrile with 0.1% formic acid twice. Samples were collected, dried in a SpeedVac concentrator, and resuspended in 0.1% formic acid for LC-MS analysis.

LC-MS analysis was performed using an EASY-nLC nano HPLC (Thermo Scientific) coupled to an Orbitrap Fusion mass spectrometer (Thermo Scientific), equipped with a nano-electrospray source. Ionization source parameters were optimized using a 2/3'-cGAMP standard (InvivoGen) and set to positive mode, capillary temperature 275 °C, spray voltage 2.3 kV. Analytes were separated on an in-house analytical column (150 µm internal diameter, 370 mm length) packed with a phenyl-hexyl resin 5 µm, 100 Å (Phenomenex). The mobile phases were 0.1% (v/v) formic acid (A) and acetonitrile with 0.1% (v/v) formic acid (B). Analytes were eluted using the following gradient: 0–20% B in 20 min, 20–98% B in 5 min and maintained over 10 min at 600 nl min<sup>-1</sup>. The mass spectrometer was set to perform a full MS scan (300–700 *m/z*) in the Orbitrap with a resolution of 120,000 (at 200 *m/z*), followed by targeted MS/MS scans of the precursor ion of cGAMP (*m/z* = 675.11 [M + H]<sup>1+</sup>). Fragment ions were scanned from 185 to 700 *m/z*. All MS/MS scans were performed in the Orbitrap mass analyser (15,000 resolution) using higher-energy collisional dissociation fragmentation (collision energy = 25), and an isolation window of 1.0 *m/z*. Maximum injection times of 50 and 100 ms were defined for MS and MS/MS scans, respectively. Automatic gain control values were set to 5 × 10<sup>5</sup> for MS and 5 × 10<sup>4</sup> for MS/MS. MS data were collected in profile mode and MS/MS data in centroid mode.

**TCGA and CCLE analyses.** The results of TCGA were based upon data generated by the TCGA Research Network (<http://cancergenome.nih.gov>). For TCGA analyses, RNA-seq data sets were obtained from cBioportal (<http://www.cbioportal.org>). For a given cancer type, tumour samples were ranked on the basis of their targeted gene expression values, and were evenly divided into four groups accordingly. Statistical comparisons were then performed between the first group (samples with the lowest 25% expression) and the last group (samples with the highest 25% expression) for inflammatory genes or the housekeeping gene (GAPDH), as denoted. Similarly, for analyses of the CCLE samples, RNA-seq data sets were obtained from the Broad Institute data portal (<http://www.portals.broadinstitute.org/ccle/home>). The samples were ranked as described above for TCGA samples, and, likewise, comparisons were performed between the first group and the last group for inflammatory genes or GAPDH. For box plots displayed in this study, the central rectangle spans a range from the first quartile to the third quartile (this range is also known as the interquartile range). A line inside the rectangle shows the median. Outliers were defined as data points that were either 1.5 × interquartile range or more above the third quartile, or 1.5 × interquartile range or more below the first quartile. If either type of outlier were present, the whisker on the appropriate side was taken to 1.5 × interquartile range from the quartile rather than the maximum or minimum. Outliers were not displayed in the box plots, but all data points were included in calculations of the *P* value. One-sided Wilcoxon rank-sum tests were used to compute statistical significance. *P* values less than 0.05 were considered significant.


**General statistical analyses.** No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. An unpaired two-tailed Student's *t*-test was used for comparison between two groups. One-way ANOVA coupled with Tukey's post hoc test was used for comparisons over two groups. All bar graphs show mean values with error bars (s.d. or s.e.m., as defined

in figure legends), unless specified otherwise; 95% confidence intervals were used, and significance was considered when *P* was less than 0.05.

**Data availability.** RNA-seq data have been uploaded to the Gene Expression Omnibus under accession number GSE99028. We declare that the data that support the findings of this study are available within the article and Supplementary Information. Related data are available from the corresponding authors upon reasonable request. No restriction on data availability applies.


31. Debacq-Chainiaux, F., Erusalimsky, J. D., Campisi, J. & Toussaint, O. Protocols to detect senescence-associated beta-galactosidase (SA-βgal) activity, a biomarker of senescent cells in culture and *in vivo*. *Nat. Protocols* **4**, 1798–1806 (2009).
32. Abe, T. *et al.* STING recognition of cytoplasmic DNA instigates cellular defense. *Mol. Cell* **50**, 5–15 (2013).
33. Wangenstein, K. J., Zhang, S., Greenbaum, L. E. & Kaestner, K. H. A genetic screen reveals Foxa3 and TNFR1 as key regulators of liver repopulation. *Genes Dev.* **29**, 904–909 (2015).
34. Freund, A., Orjalo, A. V., Desprez, P. Y. & Campisi, J. Inflammatory networks during cellular senescence: causes and consequences. *Trends Mol. Med.* **16**, 238–246 (2010).
35. Rai, T. S. & Adams, P. D. ChIP-sequencing to map the epigenome of senescent cells using benzonase endonuclease. *Methods Enzymol.* **574**, 355–364 (2016).
36. Chen, Q. *et al.* Carcinoma–astrocyte gap junctions promote brain metastasis by cGAMP transfer. *Nature* **533**, 493–498 (2016).






**Extended Data Figure 1 | CCF-cGAS-STING activation in senescence.** **a**, Confocal microscopy analyses of primary mouse embryonic fibroblasts. CCF indicated by arrows. **b**, Quantification of IMR90 undergoing replicative senescence. PD, population doubling. **c**, Microscopy-based quantification of parameters as indicated. **d-f**, Confocal microscopy analyses of BJ (**d**), IMR90 stained for endogenous cGAS (**e**), and mitotic IMR90 (**f**) cells. **g**, cGAMP detection by nano-LC-MS. MS2 spectra were

confirmed for cGAMP. **h**, IMR90 cells were analysed by immunoblotting. STING blots were performed under non-reducing condition. \* STING dimer. **i, j**, Confocal microscopy images of STING in IMR90 (**i**) and BJ (**j**) cells. **k**, Cells as in Fig. 1c were quantified under microscopy. Bar graphs show mean values of four different fields with over 200 cells and s.d. Scale bars, 10 μm.




**Extended Data Figure 2 | Interferon genes are repressed in senescent human fibroblasts.** **a, b**, ER:HRasV12 IMR90 cells were induced by OHT and quantified for CCF (**a**) or analysed by RT-qPCR (**b**). **c, d**, IMR90 cells were treated with etoposide and analysed similarly as above. Results shown in **b, d** are from triplicate technical replicates, and were normalized to the untreated sample. Bar graphs (**a, c**) show mean values of four different fields with over 200 cells and s.d. **e**, RNA-seq values of indicated genes.  $n = 3$ ; error bars, s.d. **f**, IMR90 cells were treated with a p38 inhibitor.

\* $P < 0.005$ , \*\* $P < 0.0001$ , compared with dimethylsulfoxide (DMSO). **g**, Cultured media from proliferating or senescent IMR90 cells were administered to proliferating cells, followed by dsDNA90 transfection. \* $P < 0.0001$ , compared with control media. **h**, IMR90 cells were incubated with recombinant IL1 $\alpha$  and transfected with dsDNA90. \* $P < 0.01$ , \*\* $P < 0.0001$ , compared with no-IL1 $\alpha$  transfected groups. **f-h**, RT-qPCR analyses with mean values and s.d.;  $n = 3$ ; unpaired two-tailed Student's *t*-test. **i**, Schematic illustration of interferon repression in senescence.




**Extended Data Figure 3 | CCF-cGAS-STING pathway activates the SASP.** **a**, Cells transfected with dsDNA90 were analysed by RT-qPCR. **b**, Cells as in Fig. 2c were stained for SA- $\beta$ -gal and quantified. **c**, IMR90 cells were analysed by RT-qPCR. \* $P$  < 0.0001, compared with sh-NTC etoposide. **d**, IMR90 cells were analysed by immunoblotting. **e**, Track views of indicated genes from RNA-seq. **f**, Heat map representation of SASP genes. **g**, Cultured media were analysed by IL8 immunoblotting.

**h**, Related to Fig. 2f, quantification of secreted cytokines. \* $P$  < 0.001, \*\* $P$  < 0.0001, compared with sh-NTC. **i**, **j**, RT-qPCR analyses of established senescent cells. \* $P$  < 0.005, \*\* $P$  < 0.0001, compared with +OHT sh-NTC. **j**, IFI16 does not regulate the SASP. **k**, IFI16 plays a regulatory but not essential role upon dsDNA90 transfection. Bar graphs show mean values with s.d.;  $n$  = 3; one-way ANOVA coupled with Tukey's post hoc test for **c**, **h**; unpaired two-tailed Student's  $t$ -test for **i**.




**Extended Data Figure 4 | Role of CCF-cGAS-STING in SASP activation.** a–c, IMR90 cells were analysed by confocal microscopy. \* $P < 0.005$ , compared with sh-NTC HRasV12. d, p65 Chromatin immunoprecipitation–qPCR analyses. \* $P < 0.05$ , \*\* $P < 0.01$ , compared with sh-NTC. e–h, IMR90 cells overexpressed with lamin B1 were analysed by immunofluorescence (e), immunoblotting (f, g), or RT–qPCR (h). \* $P < 0.01$ , \*\* $P < 0.001$ . i, IMR90 cells were transfected with dsDNA90 and analysed 4 days later by RT–qPCR. \* $P < 0.0001$ .

j, k, IMR90 cells were transfected with chromatin fragments, stained for H3, quantified for CCF (j), and analysed by RT–qPCR (k). \* $P < 0.005$ , \*\* $P < 0.0001$ , compared with sh-NTC transfected. Bar graphs for a–c, e, j are the average values of four different fields with over 200 cells. Error bars, s.d.;  $n = 3$  unless noted; one-way ANOVA coupled with Tukey’s post hoc test (a–d); unpaired two-tailed Student’s  $t$ -test (e, g–k). Scale bars, 10  $\mu$ m.




**Extended Data Figure 5 | Characterization of ionizing irradiation in mouse liver.** **a**, Detection of cGAMP in ionizing irradiation hepatocytes by nano-LC-MS. **b**, Control or ionizing irradiation hepatocytes of WT mice

were isolated and stained as indicated. Representative confocal images are shown. CCF are indicated by arrows. Scale bar, 5  $\mu$ m. **c**, Related to Fig. 3a, immunohistochemistry staining in no ionizing irradiation control liver.




**Extended Data Figure 6 | STING promotes Ras-induced SASP in the liver.** **a**, Immunohistochemistry of WT liver injected with NRasV12/D38A mutant. **b**, Hepatocytes of injected WT mice were isolated on day 6 and stained. CCF-positive hepatocytes were quantified. Results are average values of four different fields with over 200 cells;  $*P < 0.001$ , compared with control and NRasV12/D38A. **c**, Liver was analysed on day 6 for p21.

$n = 4$  mice. **d**, **e**, SA-β-gal analyses of liver on day 6.  $n = 3$  mice, mean with s.e.m. for **e**, **f**, Liver was analysed by immunohistochemistry on day 6 and quantified.  $n = 8$  mice;  $*P < 0.005$ ,  $**P < 0.001$ ,  $***P < 0.0005$ . **g**, Liver tumour stained for NRas. One-way ANOVA coupled with Tukey's post hoc test (**b**) and unpaired two-tailed Student's *t*-test for all others. Scale bars,  $10 \mu\text{m}$  (**b**);  $100 \mu\text{m}$  for all others. Error bars, s.e.m.



**Extended Data Figure 7 | Re-expression of STING in the null liver rescues the SASP.** **a**, Illustration of constructs used for hydrodynamic injection. **b**, Liver was harvested on day 6 and analysed by immunoblotting. **c**, Liver was harvested on day 6 and analysed by RT-qPCR.  $n = 8$  mice. **d**, Immunohistochemistry analyses of liver.


Regions with clusters of immune cells are indicated with red arrows, and a representative region is shown in inset. Scale bar,  $100\ \mu\text{m}$ . **e**, Quantification of immune cell clusters and NRas hepatocytes per field.  $n = 4$  mice,  $*P < 0.05$ ,  $**P < 0.0005$ . Unpaired two-tailed Student's  $t$ -test. Error bars, s.e.m.



**Extended Data Figure 8 | Cytoplasmic chromatin promotes pro-inflammatory responses in OIS-evaded and cancer cells.** **a**, OIS-evaded IMR90 cells were analysed by confocal microscopy. **b**, **c**, OIS-evaded IMR90 cells were analysed by RT-qPCR.  $n = 3$ ,  $*P < 0.05$ ,  $**P < 0.0001$ , compared with sh-NTC. **d**, **e**, Cancer cells were imaged under confocal microscopy; cytoplasmic chromatin indicated by arrows. **f**, Cytoplasmic chromatins were quantified and presented as normalized values from four different fields with over 200 cells.  $*P < 0.05$ ,  $**P < 0.01$ ,


$***P < 0.005$ ,  $****P < 0.0001$ , compared with control. **g**, The four cell lines were stably infected as indicated, analysed by RT-qPCR, and are presented as a heat map. **h**, Ten breast cancer cell lines were analysed for cytoplasmic chromatin and pro-inflammatory genes. Cell lines with the lowest and highest 50% of cytoplasmic chromatin were grouped and the cytokine expression levels compared. Error bars, s.e.m. for **h** and s.d. for all others; one-way ANOVA coupled with Tukey's post hoc test (**c**, **f**); unpaired two-tailed Student's *t*-test (**h**). Scale bars, 10  $\mu\text{m}$ .





**Extended Data Figure 9 | CCLE analyses of pro-inflammatory gene expression.** **a**, Related to Fig. 4g, additional genes associated with STING or lamin B1. **b**, Analyses of cGAS with pro-inflammatory gene expression profiles. Samples with the highest 25% and the lowest 25% of cGAS expression were selected and grouped; the numbers of samples

are indicated. **c**, Lamin A/C does not show negative correlation with inflammatory genes. **d**, MAVS does not correlate with pro-inflammatory gene expression. Statistical significance was judged by one-sided Wilcoxon rank-sum test. *P* values are shown for each comparison. NS, non-significant ( $P > 0.05$ ). See Methods for additional details.



**Extended Data Figure 10 | STING associates with pro-inflammatory gene expression in human cancers.** Box plots of TCGA RNA expression profiles in pancreatic adenocarcinoma (a), cutaneous melanoma (b), prostate adenocarcinoma (c), and breast adenocarcinoma (d). In each cancer type, samples with the highest 25% and the lowest 25% of STING expression were selected and grouped; the numbers of samples are

indicated. Pro-inflammatory gene expression levels were then analysed between STING-high and STING-low groups. Statistical significance was judged by one-sided Wilcoxon rank-sum test. *P* values are shown for each comparison. NS, non-significant ( $P > 0.05$ ). See Methods for additional details.

## Life Sciences Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.

For further information on the points included in this form, see [Reporting Life Sciences Research](#). For further information on Nature Research policies, including our [data availability policy](#), see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

### ► Experimental design

#### 1. Sample size

Describe how sample size was determined.

Specific sample sizes are described in figures or figure legends for all experiments. Sample size used were based on previous experience from the Berger, Adams, and Kaestner labs. No statistical test was used to pre-determine sample size.

#### 2. Data exclusions

Describe any data exclusions.

No pre-set criterion or data exclusion was used. For RNA-seq data analyses, single-ended, 75 bp reads were mildly trimmed using Trimmomatic (version 0.32) to remove leading or trailing nucleotides whose sequencing quality was below 3. Reads whose length fell below 30 bp after trimming were also removed from downstream analysis, as a standard practice.

#### 3. Replication

Describe whether the experimental findings were reliably reproduced.

The number of repeats for experiments is described in corresponding figure legends. Only successfully replicated/reproduced experiments are reported.

#### 4. Randomization

Describe how samples/organisms/participants were allocated into experimental groups.

Genotypes of mice are known to investigators. No pre-established selection criteria for mice were used, other than genotypes and ages. When mice with desired genotypes were at appropriate ages, all mice in corresponding cages were used. No selection criteria or randomization for mice applied.

#### 5. Blinding

Describe whether the investigators were blinded to group allocation during data collection and/or analysis.

The investigators were blinded when assessing IHC results. Fields or sections of tissues for quantification were randomly selected and scored, as indicated in Methods.

Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.

## 6. Statistical parameters

For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
- A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- A statement indicating how many times each experiment was replicated
- The statistical test(s) used and whether they are one- or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
- A description of any assumptions or corrections, such as an adjustment for multiple comparisons
- The test results (e.g.  $P$  values) given as exact values whenever possible and with confidence intervals noted
- A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
- Clearly defined error bars

See the web collection on [statistics for biologists](#) for further resources and guidance.

## ► Software

Policy information about [availability of computer code](#)

## 7. Software

Describe the software used to analyze the data in this study.

Excel and GraphPad were used to perform general statistical analyses. For RNA-seq data analyses, the following published software were used: Trimmomatic (version 0.32), STAR (version 2.3.0e), and featureCounts (version 1.5.0).

For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). [Nature Methods guidance for providing algorithms and software for publication](#) provides further information on this topic.

## ► Materials and reagents

Policy information about [availability of materials](#)

## 8. Materials availability

Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.

No unique materials were used.

## 9. Antibodies

Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).

A detailed description of antibodies used, including vendors and catalog numbers, was provided in Methods, under "Reagents and antibodies" section. Antibodies were validated by gene inactivation and/or biological effects, and by other published studies.

## 10. Eukaryotic cell lines

a. State the source of each eukaryotic cell line used.

Primary BJ fibroblasts were purchased from ATCC, IMR90 from Coriell, and were described in previous studies.

b. Describe the method of cell line authentication used.

IMR90 and BJ were authenticated by previous genome-wide sequencing analyses.

c. Report whether the cell lines were tested for mycoplasma contamination.

Cells were intermittently tested for mycoplasma.

d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by [ICLAC](#), provide a scientific rationale for their use.

N/A.

## ► Animals and human research participants

---

Policy information about [studies involving animals](#); when reporting animal research, follow the [ARRIVE guidelines](#)

### 11. Description of research animals

Provide details on animals and/or animal-derived materials used in the study.

STING+/+ and STING-/- mice in C57BL/6 background were described previously. Mice were fed ad libitum on a regular diet, and handled following institutional regulations and guidelines. Both sexes were included in the study.

Policy information about [studies involving human research participants](#)

### 12. Description of human research participants

Describe the covariate-relevant population characteristics of the human research participants.

N/A.